Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ARANASDAQ:MESONASDAQ:SDGRNASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAAmerican Renal Associates$11.52$11.50$5.57▼$11.98$397.94M1.11106,940 shs9,831 shsMESOMesoblast$10.79-0.6%$11.30$5.78▼$22.00$1.36B2.39277,456 shs208,906 shsSDGRSchrodinger$20.96$22.66$16.60▼$28.47$1.55B1.58914,852 shs348,387 shsSPRYARS Pharmaceuticals$16.49-1.6%$14.85$8.91▼$18.90$1.62B0.91.34 million shs881,491 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAAmerican Renal Associates0.00%0.00%0.00%0.00%0.00%MESOMesoblast0.00%-1.19%-7.06%+2.08%+58.56%SDGRSchrodinger0.00%+1.70%-12.08%+16.25%+4.28%SPRYARS Pharmaceuticals0.00%-9.42%+22.66%+28.79%+81.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARAAmerican Renal AssociatesN/AN/AN/AN/AN/AN/AN/AN/AMESOMesoblast2.3677 of 5 stars3.51.00.00.03.70.80.6SDGRSchrodinger2.7882 of 5 stars3.42.00.00.02.92.50.6SPRYARS Pharmaceuticals3.2393 of 5 stars3.61.00.00.03.24.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAAmerican Renal Associates 0.00N/AN/AN/AMESOMesoblast 3.00Buy$18.0066.82% UpsideSDGRSchrodinger 2.75Moderate Buy$33.2558.64% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.0088.05% UpsideCurrent Analyst Ratings BreakdownLatest ARA, SPRY, MESO, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$28.004/16/2025SDGRSchrodingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAAmerican Renal Associates$822.52M0.48$1.69 per share6.80$2.59 per share4.45MESOMesoblast$5.67M243.16N/AN/A$4.21 per share2.56SDGRSchrodinger$207.54M7.41N/AN/A$5.78 per share3.63SPRYARS Pharmaceuticals$89.15M18.16$0.01 per share1,950.80$2.64 per share6.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAAmerican Renal Associates-$13.79M$0.26N/AN/AN/A-2.04%-3.56%-0.24%N/AMESOMesoblast-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.16N/AN/AN/A-16.11%-6.94%-5.60%8/5/2025 (Estimated)Latest ARA, SPRY, MESO, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025SDGRSchrodinger-$0.83N/AN/AN/A$52.03 millionN/A5/14/2025Q1 2025SPRYARS Pharmaceuticals-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million5/7/2025Q1 2025SDGRSchrodinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAAmerican Renal AssociatesN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAAmerican Renal Associates7.541.051.02MESOMesoblast0.220.960.63SDGRSchrodingerN/A3.453.45SPRYARS Pharmaceuticals0.3011.0010.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAAmerican Renal Associates78.42%MESOMesoblast1.43%SDGRSchrodinger79.05%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipARAAmerican Renal Associates9.50%MESOMesoblast18.80%SDGRSchrodinger8.60%SPRYARS Pharmaceuticals33.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAAmerican Renal Associates4,97734.54 millionN/AOptionableMESOMesoblast80127.78 million103.76 millionOptionableSDGRSchrodinger79073.38 million67.07 millionOptionableSPRYARS Pharmaceuticals9098.21 million65.31 millionOptionableARA, SPRY, MESO, and SDGR HeadlinesRecent News About These CompaniesAllspring Global Investments Holdings LLC Raises Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)2 hours ago | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $254,850.00 in StockJuly 4 at 7:48 AM | insidertrades.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 15,000 Shares of StockJuly 3 at 6:41 PM | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder James E. Flynn Sells 740,149 SharesJuly 2, 2025 | insidertrades.comJames E. Flynn Sells 740,149 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockJuly 1, 2025 | marketbeat.comPeregrine Capital Management LLC Boosts Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)July 1, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5% - Here's What HappenedJune 30, 2025 | marketbeat.comLisanti Capital Growth LLC Buys New Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)June 29, 2025 | marketbeat.com55,714 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Purchased by Matisse CapitalJune 28, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Upgraded to "Hold" at Wall Street ZenJune 28, 2025 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Upgraded at Wall Street ZenJune 28, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Sets New 12-Month High - Still a Buy?June 27, 2025 | marketbeat.comLeerink Partnrs Analysts Raise Earnings Estimates for SPRYJune 26, 2025 | americanbankingnews.comQ2 EPS Estimate for ARS Pharmaceuticals Boosted by AnalystJune 25, 2025 | marketbeat.comHarbour Capital Advisors LLC Purchases New Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)June 25, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by AssuredPartners Investment Advisors LLCJune 25, 2025 | marketbeat.comBrokers Offer Predictions for SPRY FY2029 EarningsJune 24, 2025 | marketbeat.comJanney Montgomery Scott LLC Boosts Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)June 23, 2025 | marketbeat.comEric Karas Sells 15,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockJune 20, 2025 | marketbeat.com249,230 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Advisor Resource CouncilJune 20, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by BrokeragesJune 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIgnore the Noise—Samsara Stock Is Still a Strong BuyBy Sam Quirke | June 12, 2025View Ignore the Noise—Samsara Stock Is Still a Strong BuyWill Warner Bros. Discovery’s Split Produce Double the Upside?By Jeffrey Neal Johnson | June 11, 2025View Will Warner Bros. Discovery’s Split Produce Double the Upside?Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsBy Nathan Reiff | June 30, 2025View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsJPMorgan Chase: The Financial Fortress Built for Today's InvestorBy Jeffrey Neal Johnson | June 23, 2025View JPMorgan Chase: The Financial Fortress Built for Today's InvestorARA, SPRY, MESO, and SDGR Company DescriptionsAmerican Renal Associates NYSE:ARAAmerican Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.Mesoblast NASDAQ:MESO$10.79 -0.07 (-0.64%) Closing price 07/3/2025 03:26 PM EasternExtended Trading$10.79 0.00 (0.00%) As of 07/3/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Schrodinger NASDAQ:SDGR$20.96 0.00 (0.00%) Closing price 07/3/2025 03:29 PM EasternExtended Trading$21.04 +0.08 (+0.38%) As of 07/3/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.ARS Pharmaceuticals NASDAQ:SPRY$16.48 -0.27 (-1.58%) Closing price 07/3/2025 03:38 PM EasternExtended Trading$16.52 +0.04 (+0.21%) As of 07/3/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
